{"entity":{"type":"insider","cik":"0001397266","url":"/insider/0001397266","json_url":"/insider/0001397266.json","name":"Fust Matthew K","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":53,"n_filings":41,"first":"2010-01-07","last":"2025-09-30","span_basis":"filed_date"},"name_variants":[{"name":"Fust Matthew K","source":"filing","n_filings":41,"first_seen":"2010-01-07","last_seen":"2025-09-30"}],"transactions":[{"id":4678091,"accession":"0001658247-25-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001658247-25-000010","line_url":"/filing/0001658247-25-000010#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16000.0,"shares_display":"16,000","price_per_share":44.75,"price_display":"44.75","price_state":"stated","total_value":716000.0,"total_display":"716,000.00","total_whole":"716,000","shares_owned_after":22836.0,"shares_owned_after_display":"22,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-26","filed_date":"2025-09-30","scope":"insider"},{"id":2488871,"accession":"0001610717-24-000511","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001610717-24-000511","line_url":"/filing/0001610717-24-000511#line-7","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14049.0,"shares_display":"14,049","price_per_share":17.0346,"price_display":"17.03","price_state":"stated","total_value":239319.0954,"total_display":"239,319.10","total_whole":"239,319","shares_owned_after":20100.0,"shares_owned_after_display":"20,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-18","filed_date":"2024-10-18","scope":"insider"},{"id":2488862,"accession":"0001610717-24-000511","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001610717-24-000511","line_url":"/filing/0001610717-24-000511#line-4","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7739.0,"shares_display":"7,739","price_per_share":17.0103,"price_display":"17.01","price_state":"stated","total_value":131642.7117,"total_display":"131,642.71","total_whole":"131,643","shares_owned_after":20100.0,"shares_owned_after_display":"20,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-17","filed_date":"2024-10-18","scope":"insider"},{"id":3042420,"accession":"0001209191-24-005060","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-24-005060","line_url":"/filing/0001209191-24-005060","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60000.0,"shares_display":"60,000","price_per_share":44.13583333333333,"price_display":"44.14","price_state":"stated","total_value":2648150.0,"total_display":"2,648,150.00","total_whole":"2,648,150","shares_owned_after":18536.0,"shares_owned_after_display":"18,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-20","filed_date":"2024-03-22","scope":"insider","n_lines":4},{"id":2983396,"accession":"0000950170-24-029040","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-029040","line_url":"/filing/0000950170-24-029040","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12195.0,"shares_display":"12,195","price_per_share":50.87681426814268,"price_display":"50.88","price_state":"stated","total_value":620442.75,"total_display":"620,442.75","total_whole":"620,443","shares_owned_after":14860.0,"shares_owned_after_display":"14,860","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-07","filed_date":"2024-03-11","scope":"insider","n_lines":3},{"id":6631133,"accession":"0001209191-22-042245","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-042245","line_url":"/filing/0001209191-22-042245#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5700.0,"shares_display":"5,700","price_per_share":20.957,"price_display":"20.96","price_state":"stated","total_value":119454.9,"total_display":"119,454.90","total_whole":"119,455","shares_owned_after":12536.0,"shares_owned_after_display":"12,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-13","filed_date":"2022-07-15","scope":"insider"},{"id":5009076,"accession":"0001567619-21-019403","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-019403","line_url":"/filing/0001567619-21-019403#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13354.0,"shares_display":"13,354","price_per_share":19.5,"price_display":"19.50","price_state":"stated","total_value":260403.0,"total_display":"260,403.00","total_whole":"260,403","shares_owned_after":31500.0,"shares_owned_after_display":"31,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-04","filed_date":"2021-11-05","scope":"insider"},{"id":4148028,"accession":"0001209191-21-062728","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-062728","line_url":"/filing/0001209191-21-062728#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8954.0,"shares_display":"8,954","price_per_share":25.5,"price_display":"25.50","price_state":"stated","total_value":228327.0,"total_display":"228,327.00","total_whole":"228,327","shares_owned_after":12536.0,"shares_owned_after_display":"12,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-01","filed_date":"2021-11-03","scope":"insider"},{"id":5530593,"accession":"0001209191-21-055314","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-055314","line_url":"/filing/0001209191-21-055314#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6046.0,"shares_display":"6,046","price_per_share":25.5,"price_display":"25.50","price_state":"stated","total_value":154173.0,"total_display":"154,173.00","total_whole":"154,173","shares_owned_after":12536.0,"shares_owned_after_display":"12,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-08","filed_date":"2021-09-09","scope":"insider"},{"id":5201119,"accession":"0001209191-21-048375","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-048375","line_url":"/filing/0001209191-21-048375#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":19.59,"price_display":"19.59","price_state":"stated","total_value":97950.0,"total_display":"97,950.00","total_whole":"97,950","shares_owned_after":12536.0,"shares_owned_after_display":"12,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-26","filed_date":"2021-07-27","scope":"insider"},{"id":4141429,"accession":"0001209191-21-047402","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-047402","line_url":"/filing/0001209191-21-047402#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":19.5,"price_display":"19.50","price_state":"stated","total_value":97500.0,"total_display":"97,500.00","total_whole":"97,500","shares_owned_after":12536.0,"shares_owned_after_display":"12,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-19","filed_date":"2021-07-20","scope":"insider"},{"id":4787153,"accession":"0001209191-21-046554","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-046554","line_url":"/filing/0001209191-21-046554#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":20.71,"price_display":"20.71","price_state":"stated","total_value":103550.0,"total_display":"103,550.00","total_whole":"103,550","shares_owned_after":12536.0,"shares_owned_after_display":"12,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-12","filed_date":"2021-07-13","scope":"insider"},{"id":2545296,"accession":"0001209191-20-041644","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-041644","line_url":"/filing/0001209191-20-041644#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6181.0,"shares_display":"6,181","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":556290.0,"total_display":"556,290.00","total_whole":"556,290","shares_owned_after":13550.0,"shares_owned_after_display":"13,550","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-07-06","filed_date":"2020-07-08","scope":"insider"},{"id":2041569,"accession":"0001209191-20-040945","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-040945","line_url":"/filing/0001209191-20-040945#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":85.0,"price_display":"85.00","price_state":"stated","total_value":425000.0,"total_display":"425,000.00","total_whole":"425,000","shares_owned_after":13550.0,"shares_owned_after_display":"13,550","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-07-01","filed_date":"2020-07-06","scope":"insider"},{"id":2337324,"accession":"0001209191-20-030709","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-030709","line_url":"/filing/0001209191-20-030709#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1875.0,"shares_display":"1,875","price_per_share":75.0,"price_display":"75.00","price_state":"stated","total_value":140625.0,"total_display":"140,625.00","total_whole":"140,625","shares_owned_after":11000.0,"shares_owned_after_display":"11,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-18","filed_date":"2020-05-19","scope":"insider"},{"id":2468879,"accession":"0001209191-20-025550","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-025550","line_url":"/filing/0001209191-20-025550#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1875.0,"shares_display":"1,875","price_per_share":65.0,"price_display":"65.00","price_state":"stated","total_value":121875.0,"total_display":"121,875.00","total_whole":"121,875","shares_owned_after":12875.0,"shares_owned_after_display":"12,875","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-04-22","filed_date":"2020-04-24","scope":"insider"},{"id":7796658,"accession":"0001562180-19-006267","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-19-006267","line_url":"/filing/0001562180-19-006267#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Dermira, Inc.","issuer_ticker":"DERM","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":45000.0,"total_display":"45,000.00","total_whole":"45,000","shares_owned_after":5051.0,"shares_owned_after_display":"5,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-24","filed_date":"2019-12-26","scope":"insider"},{"id":8570104,"accession":"0001209191-19-061184","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-061184","line_url":"/filing/0001209191-19-061184#line-2","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3500.0,"shares_display":"3,500","price_per_share":22.5,"price_display":"22.50","price_state":"stated","total_value":78750.0,"total_display":"78,750.00","total_whole":"78,750","shares_owned_after":12536.0,"shares_owned_after_display":"12,536","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-16","filed_date":"2019-12-18","scope":"insider"},{"id":8268874,"accession":"0001562180-19-006079","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-19-006079","line_url":"/filing/0001562180-19-006079#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Dermira, Inc.","issuer_ticker":"DERM","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":36000.0,"total_display":"36,000.00","total_whole":"36,000","shares_owned_after":8051.0,"shares_owned_after_display":"8,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-12","filed_date":"2019-12-13","scope":"insider"},{"id":8609531,"accession":"0001562180-19-004818","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-19-004818","line_url":"/filing/0001562180-19-004818#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Dermira, Inc.","issuer_ticker":"DERM","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":8.7727,"price_display":"8.77","price_state":"stated","total_value":52636.2,"total_display":"52,636.20","total_whole":"52,636","shares_owned_after":11051.0,"shares_owned_after_display":"11,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-12","filed_date":"2019-09-16","scope":"insider"},{"id":8093730,"accession":"0001125345-19-000018","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001125345-19-000018","line_url":"/filing/0001125345-19-000018#line-2","is_derivative":false,"issuer_cik":"0001125345","issuer_name":"MACROGENICS INC","issuer_ticker":"MGNX","issuer_name_source":null,"issuer_url":"/issuer/0001125345","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6924.0,"shares_display":"6,924","price_per_share":29.38,"price_display":"29.38","price_state":"stated","total_value":203427.12,"total_display":"203,427.12","total_whole":"203,427","shares_owned_after":500.0,"shares_owned_after_display":"500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-06","filed_date":"2019-02-08","scope":"insider"},{"id":6505000,"accession":"0001562180-18-004253","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-18-004253","line_url":"/filing/0001562180-18-004253#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Dermira, Inc.","issuer_ticker":"DERM","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":13.75,"price_display":"13.75","price_state":"stated","total_value":55000.0,"total_display":"55,000.00","total_whole":"55,000","shares_owned_after":14051.0,"shares_owned_after_display":"14,051","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-19","filed_date":"2018-10-19","scope":"insider"},{"id":6706348,"accession":"0001209191-18-034278","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-034278","line_url":"/filing/0001209191-18-034278#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6319.0,"shares_display":"6,319","price_per_share":72.0002,"price_display":"72.00","price_state":"stated","total_value":454969.2638,"total_display":"454,969.26","total_whole":"454,969","shares_owned_after":8750.0,"shares_owned_after_display":"8,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-05-30","scope":"insider"},{"id":6043749,"accession":"0001209191-18-030726","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-030726","line_url":"/filing/0001209191-18-030726#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Atara Biotherapeutics, Inc.","issuer_ticker":"ATRA","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12286.0,"shares_display":"12,286","price_per_share":43.57,"price_display":"43.57","price_state":"stated","total_value":535301.02,"total_display":"535,301.02","total_whole":"535,301","shares_owned_after":19820.0,"shares_owned_after_display":"19,820","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-05-14","filed_date":"2018-05-16","scope":"insider"},{"id":6772893,"accession":"0001140361-14-043609","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-14-043609","line_url":"/filing/0001140361-14-043609#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Dermira, Inc.","issuer_ticker":"DERM","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6000.0,"shares_display":"6,000","price_per_share":16.7674,"price_display":"16.77","price_state":"stated","total_value":100604.4,"total_display":"100,604.40","total_whole":"100,604","shares_owned_after":6000.0,"shares_owned_after_display":"6,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-25","filed_date":"2014-11-26","scope":"insider"},{"id":6908300,"accession":"0001209191-14-006664","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-006664","line_url":"/filing/0001209191-14-006664#line-1","is_derivative":false,"issuer_cik":"0001397266","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001397266","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":105000.0,"total_display":"105,000.00","total_whole":"105,000","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-30","filed_date":"2014-02-03","scope":"insider"},{"id":4470142,"accession":"0001179110-13-013051","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-13-013051","line_url":"/filing/0001179110-13-013051#line-1","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2492.0,"shares_display":"2,492","price_per_share":128.21,"price_display":"128.21","price_state":"stated","total_value":319499.32,"total_display":"319,499.32","total_whole":"319,499","shares_owned_after":40303.0,"shares_owned_after_display":"40,303","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-08-08","filed_date":"2013-08-12","scope":"insider"},{"id":5445247,"accession":"0001179110-13-012260","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-13-012260","line_url":"/filing/0001179110-13-012260#line-1","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6043.0,"shares_display":"6,043","price_per_share":130.5,"price_display":"130.50","price_state":"stated","total_value":788611.5,"total_display":"788,611.50","total_whole":"788,612","shares_owned_after":42795.0,"shares_owned_after_display":"42,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-26","filed_date":"2013-07-29","scope":"insider"},{"id":5161702,"accession":"0001179110-13-011583","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-13-011583","line_url":"/filing/0001179110-13-011583","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1551.0,"shares_display":"1,551","price_per_share":132.8,"price_display":"132.80","price_state":"stated","total_value":205972.8,"total_display":"205,972.80","total_whole":"205,973","shares_owned_after":48961.0,"shares_owned_after_display":"48,961","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-02","filed_date":"2013-07-05","scope":"insider","n_lines":2},{"id":5249784,"accession":"0001179110-13-008495","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001179110-13-008495","line_url":"/filing/0001179110-13-008495","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10269.0,"shares_display":"10,269","price_per_share":98.21776803973123,"price_display":"98.22","price_state":"stated","total_value":1008598.26,"total_display":"1,008,598.26","total_whole":"1,008,598","shares_owned_after":50204.0,"shares_owned_after_display":"50,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-13","filed_date":"2013-05-15","scope":"insider","n_lines":2},{"id":5503850,"accession":"0001179110-13-006838","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-13-006838","line_url":"/filing/0001179110-13-006838#line-1","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1347.0,"shares_display":"1,347","price_per_share":95.15,"price_display":"95.15","price_state":"stated","total_value":128167.05,"total_display":"128,167.05","total_whole":"128,167","shares_owned_after":50204.0,"shares_owned_after_display":"50,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-04-15","filed_date":"2013-04-16","scope":"insider"},{"id":5503705,"accession":"0001179110-13-006440","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-13-006440","line_url":"/filing/0001179110-13-006440","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3861.0,"shares_display":"3,861","price_per_share":86.13697746697747,"price_display":"86.14","price_state":"stated","total_value":332574.87,"total_display":"332,574.87","total_whole":"332,575","shares_owned_after":51551.0,"shares_owned_after_display":"51,551","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-04-01","filed_date":"2013-04-03","scope":"insider","n_lines":2},{"id":5503613,"accession":"0001179110-13-004074","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001179110-13-004074","line_url":"/filing/0001179110-13-004074#line-2","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":77.12,"price_display":"77.12","price_state":"stated","total_value":1156800.0,"total_display":"1,156,800.00","total_whole":"1,156,800","shares_owned_after":45201.0,"shares_owned_after_display":"45,201","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-02-28","filed_date":"2013-03-04","scope":"insider"},{"id":5386052,"accession":"0001179110-13-000808","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001179110-13-000808","line_url":"/filing/0001179110-13-000808","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (EVP & Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10199.0,"shares_display":"10,199","price_per_share":84.86931758015491,"price_display":"84.87","price_state":"stated","total_value":865582.17,"total_display":"865,582.17","total_whole":"865,582","shares_owned_after":53500.0,"shares_owned_after_display":"53,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-10","filed_date":"2013-01-11","scope":"insider","n_lines":2},{"id":3325852,"accession":"0001209191-12-041040","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-12-041040","line_url":"/filing/0001209191-12-041040","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22009.0,"shares_display":"22,009","price_per_share":71.71005361443046,"price_display":"71.71","price_state":"stated","total_value":1578266.57,"total_display":"1,578,266.57","total_whole":"1,578,267","shares_owned_after":70416.0,"shares_owned_after_display":"70,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-08-06","filed_date":"2012-08-08","scope":"insider","n_lines":3},{"id":3189895,"accession":"0001209191-12-039432","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-039432","line_url":"/filing/0001209191-12-039432#line-1","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5207.0,"shares_display":"5,207","price_per_share":73.9717,"price_display":"73.97","price_state":"stated","total_value":385170.6419,"total_display":"385,170.64","total_whole":"385,171","shares_owned_after":67924.0,"shares_owned_after_display":"67,924","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-07-25","filed_date":"2012-07-27","scope":"insider"},{"id":3173999,"accession":"0001209191-12-016274","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-016274","line_url":"/filing/0001209191-12-016274#line-1","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":592.0,"shares_display":"592","price_per_share":37.52,"price_display":"37.52","price_state":"stated","total_value":22211.84,"total_display":"22,211.84","total_whole":"22,212","shares_owned_after":48237.0,"shares_owned_after_display":"48,237","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-02","filed_date":"2012-03-06","scope":"insider"},{"id":3494684,"accession":"0001209191-12-003129","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-003129","line_url":"/filing/0001209191-12-003129#line-1","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1789.0,"shares_display":"1,789","price_per_share":43.46,"price_display":"43.46","price_state":"stated","total_value":77749.94,"total_display":"77,749.94","total_whole":"77,750","shares_owned_after":43829.0,"shares_owned_after_display":"43,829","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-01-06","filed_date":"2012-01-10","scope":"insider"},{"id":9075467,"accession":"0001209191-11-057407","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-057407","line_url":"/filing/0001209191-11-057407#line-1","is_derivative":false,"issuer_cik":"0001012140","issuer_name":"ONYX PHARMACEUTICALS INC","issuer_ticker":"ONXX","issuer_name_source":null,"issuer_url":"/issuer/0001012140","owner_cik":"0001397266","owner_name":"Fust Matthew K","owner_display_name":"Fust Matthew K","owner_url":"/insider/0001397266","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":867.0,"shares_display":"867","price_per_share":38.05,"price_display":"38.05","price_state":"stated","total_value":32989.35,"total_display":"32,989.35","total_whole":"32,989","shares_owned_after":45310.0,"shares_owned_after_display":"45,310","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-11-18","filed_date":"2011-11-21","scope":"insider"}],"collapsed":true,"next_cursor":"2011-11-18|9075467","ledger_fault":false,"count":{"value":53,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":51,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":53},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001658247","name":"Crinetics Pharmaceuticals, Inc.","url":"/issuer/0001658247","role":"Director","n_filings":9,"first_seen":"2019-12-18","last_seen":"2025-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001885522","name":"Neumora Therapeutics, Inc.","url":"/issuer/0001885522","role":"Director","n_filings":1,"first_seen":"2024-10-18","last_seen":"2024-10-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Director","n_filings":7,"first_seen":"2014-02-03","last_seen":"2024-03-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001604464","name":"Atara Biotherapeutics, Inc.","url":"/issuer/0001604464","role":"Director","n_filings":2,"first_seen":"2018-05-16","last_seen":"2021-11-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001557883","name":"Dermira, Inc.","url":"/issuer/0001557883","role":"Director","n_filings":5,"first_seen":"2014-11-26","last_seen":"2019-12-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001125345","name":"MACROGENICS INC","url":"/issuer/0001125345","role":"Director","n_filings":1,"first_seen":"2019-02-08","last_seen":"2019-02-08"},{"type":"issuer","type_label":"ISSUER","cik":"0001012140","name":"ONYX PHARMACEUTICALS INC","url":"/issuer/0001012140","role":"Officer (EVP & Chief Financial Officer)","n_filings":16,"first_seen":"2010-01-07","last_seen":"2013-08-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001397266","retrieved_at":"2026-08-27T15:28:01+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}